Drug intelligence / Profile preview

SBM-07

Development stage: Unknown
Lead developer: Shilpa Biologicals
Modality: Peptides

Overview

SBM-07, also identified as Peptide-ARBM 101, is a therapeutic peptide currently in Phase 1 clinical development by Shilpa Biologicals, a subsidiary of Shilpa Medicare. The specific therapeutic indication and molecular target for SBM-07 are currently undisclosed, as the project is listed as confidential by the developer. Shilpa Biologicals focuses on the development and manufacture of biologics, including biosimilars and novel peptides, often operating as a partner or CDMO for other pharmaceutical entities.

Other names: Peptide-ARBM 101Peptide-ARBM101Peptide-ARBM-101

Targets

IGF-1R (Insulin-like growth factor 1 receptor)INSR (Insulin receptor)

Beyond the preview

Go deeper on SBM-07.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SBM-07.

Explore the full profile